Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

Published:2018-04-20 Issue:7 Volume:19 Page:713-738
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Rossetti Barbara¹²,Montagnani Francesca¹³,De Luca Andrea¹³

Affiliation:

1. Infectious Diseases Unit, Hospital Department of Specialized and Internal Medicine, University Hospital of Siena, Siena, Italy

2. Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy

3. Department of Medical Biotechnologies, Infectious Diseases Division, University of Siena, Siena, Italy

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1457648

Reference65 articles.

1. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

3. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen;International Journal of Antimicrobial Agents;2023-05

2. New designs for HIV-1 integrase inhibitors: a patent review (2018-present);Expert Opinion on Therapeutic Patents;2023-01-02

3. Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1—Infected Patients With High-Level Viral Load: Preliminary Data From the Real World;JAIDS Journal of Acquired Immune Deficiency Syndromes;2022-10-01

4. Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial;2022-07-09

5. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting;HIV Research & Clinical Practice;2022-06-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3